Business Context and Reporting Period
Company: Neurogene Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2026
Reporting Period: Single event date (February 26, 2026)
This filing reports a material corporate event under Item 7.01 (Regulation FD Disclosure). Neurogene Inc. announced that its investigational gene therapy, NGN-401, intended for the treatment of Rett syndrome, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a regulatory milestone and does not contain financial statements or quantitative financial data.
Material Changes
Regulatory Milestone: The primary material change is the receipt of Breakthrough Therapy Designation for NGN-401 by the FDA. This designation is intended to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the FDA designation. The text notes that NGN-401 is in late-stage clinical development.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly set forth. No specific financial risks or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific details on the Breakthrough Therapy Designation criteria.
- Confirm the current clinical trial phase and patient enrollment status for NGN-401.
- Review recent 10-K or 10-Q filings for the company's cash runway and funding requirements, as this 8-K contains no financial data.
- Monitor for future FDA communications regarding the development timeline for NGN-401 following this designation.